S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
Russia accused of 'kidnapping' head of Ukraine nuclear plant
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
UK train strikes and energy hikes add to a week of turmoil
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
Russia blindfolds, detains Ukraine nuclear plant chief
Ruptured oil pipeline off California approved for repairs
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
Russia accused of 'kidnapping' head of Ukraine nuclear plant
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
UK train strikes and energy hikes add to a week of turmoil
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
Russia blindfolds, detains Ukraine nuclear plant chief
Ruptured oil pipeline off California approved for repairs
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
Russia accused of 'kidnapping' head of Ukraine nuclear plant
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
UK train strikes and energy hikes add to a week of turmoil
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
Russia blindfolds, detains Ukraine nuclear plant chief
Ruptured oil pipeline off California approved for repairs
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
Russia accused of 'kidnapping' head of Ukraine nuclear plant
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
UK train strikes and energy hikes add to a week of turmoil
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
Russia blindfolds, detains Ukraine nuclear plant chief
Ruptured oil pipeline off California approved for repairs
OTCMKTS:ASPCF

Acerus Pharmaceuticals - ASPCF Stock Forecast, Price & News

$1.32
-0.53 (-28.59%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.32
$1.33
50-Day Range
$1.32
$2.25
52-Week Range
$1.32
$8.16
Volume
2,275 shs
Average Volume
46 shs
Market Capitalization
$10.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ASPCF stock logo

About Acerus Pharmaceuticals (OTCMKTS:ASPCF) Stock

Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; and Noctiva, a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Tefina, a clinical stage product for women with female sexual dysfunction; and Noctiva combination products, which are in the pre-clinical development stage for the treatment of benign prostatic hypertrophy, overactive bladder, and pediatric nocturnal enuresis. In addition, the company provides TriVair technology platform for pulmonary and nasal dosing. It sells its products through its salesforce in the United States and Canada; and through a network of distributors internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.

Receive ASPCF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acerus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ASPCF Stock News Headlines

Acerus Pharmaceuticals (OTCMKTS:ASPCF) Trading Down 28.5%
Acerus Pharmaceuticals (OTCMKTS:ASPCF) Shares Down 28.5%
Acerus Announces Initiation of Strategic Review
Acerus Announces Completion of Share Consolidation
Acerus Announces Share Consolidation
See More Headlines
Receive ASPCF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acerus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ASPCF Company Calendar

Last Earnings
8/08/2022
Today
10/02/2022
Next Earnings (Estimated)
11/07/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:ASPCF
CIK
N/A
Employees
14
Year Founded
N/A

Profitability

Net Income
$-33,820,000.00
Net Margins
-1,008.97%
Pretax Margin
-1,008.97%

Debt

Sales & Book Value

Annual Sales
$2.12 million
Book Value
($3.38) per share

Miscellaneous

Free Float
N/A
Market Cap
$10.20 million
Optionable
Not Optionable
Beta
0.90

Key Executives

  • Mr. Edward Gudaitis
    Pres, CEO & Director
  • Mr. Robert M. Motz
    Chief Financial Officer
  • Mr. Gavin Damstra
    Sr. VP of International Commercial
  • Dr. Christopher Sorli F.A.C.E.
    M.D., Ph.D., Chief Medical Officer
  • Mr. Kevin Thomas Hickey
    Sr. VP of US Commercial
  • Mr. Chris Witty
    Investor Relations
  • Mr. Philippe Savard
    VP, Gen. Counsel & Corp. Sec.
  • Mr. Hubert Tomasz Czerwinski
    Pres of Acerus Pharmaceuticals SRL













ASPCF Stock - Frequently Asked Questions

How have ASPCF shares performed in 2022?

Acerus Pharmaceuticals' stock was trading at $4.06 on January 1st, 2022. Since then, ASPCF shares have decreased by 67.4% and is now trading at $1.3235.
View the best growth stocks for 2022 here
.

When is Acerus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 7th 2022.
View our ASPCF earnings forecast
.

How were Acerus Pharmaceuticals' earnings last quarter?

Acerus Pharmaceuticals Co. (OTCMKTS:ASPCF) released its earnings results on Monday, August, 8th. The company reported ($1.03) earnings per share (EPS) for the quarter. The company earned $0.75 million during the quarter.

When did Acerus Pharmaceuticals' stock split?

Shares of Acerus Pharmaceuticals reverse split before market open on Friday, April 29th 2022. The 1-200 reverse split was announced on Friday, April 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

What is Acerus Pharmaceuticals' stock symbol?

Acerus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ASPCF."

How do I buy shares of Acerus Pharmaceuticals?

Shares of ASPCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Acerus Pharmaceuticals' stock price today?

One share of ASPCF stock can currently be purchased for approximately $1.32.

How much money does Acerus Pharmaceuticals make?

Acerus Pharmaceuticals (OTCMKTS:ASPCF) has a market capitalization of $10.20 million and generates $2.12 million in revenue each year. The company earns $-33,820,000.00 in net income (profit) each year or ($3.03) on an earnings per share basis.

How can I contact Acerus Pharmaceuticals?

Acerus Pharmaceuticals' mailing address is 2486 Dunwin Drive, Mississauga A6, L5L 1J9. The official website for the company is www.aceruspharma.com. The company can be reached via phone at (416) 679-0771, via email at ir@aceruspharma.com, or via fax at 905-569-1809.

This page (OTCMKTS:ASPCF) was last updated on 10/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.